SRSF3 was directly associated with the development, progression and aggressiveness of glioblastoma and also correlated with patient survival. This gene represents a novel therapeutic target that warrants clinical testing.
Why this matters
There is emerging data that indicate gene splicing mechanisms are altered in tumors, which lead to oncogenic splicing events associated with the progression and aggressiveness of tumors.
The results from this study provide valuable insights of the splicing machinery in glioblastomas and to developing novel strategies to support the diagnosis, prognosis and treatment of glioblastomas.